IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Events with Major Potential Impact for Takeda
EVENT SUMMARY
Multiple patent expirations Takeda’s four mainstay global strategic products lose patent protection
over the next five years: Prevacid (lansoprazole) in November 2009
followed by Actos (pioglitazone) in 2011 and then Blopress
(candesartan) in 2012 and Leuplin (leuprorelin) in 2014. The patent
expiration of Actos and Prevacid alone is expected to amount to annual
losses of over Yen500 billion in 2009 through 2011.
Transformative Millennium
acquisition
TAP buyout to boost US
status
Delayed review of
alogliptin and Actos
expansion
Pending launches of
Kapidex and Uloric in the
US
The Yen1 trillion acquisition of Millennium has been described as the
most significant and strategically transformative deal in Takeda’s history
and will help it realize its goal of becoming one of the top three oncology
companies.
After 30 years together, Takeda decided to dissolve the TAP jv with
Abbott from mid-2008 and paid $1.5 billion for Abbott’s share of the jv,
gaining full rights to Takepron and losing Leuplin. The 50% share in TAP
has been fully integrated into Takeda’s growing stand-alone operation,
Takeda Pharmaceuticals North America (TPNA) and Takeda hopes its
presence in the US will be boosted to rank in the top 15.
The FDA review of alogliptin, the follow-on to Actos, is delayed until June
2009, a delay of eight months from the original date and it now lags well
behind Merck &Co’s Januvia (sitagliptin), which has become the ‘gold
standard’ for the DPP-IV inhibitor class, with new products expected to
show superiority. Analysts so far seem to be of the opinion that alogliptin
only offers similar safety and efficacy to Januvia, although Takeda may
benefit from greater experience in diabetes, as well as approval of a pill
combining alogliptin with Actos, expected in the second half of 2009.
The latest approvals of Prevacid (lansoprazole) follow-on Kapidex (TAK
390MR) for peptic ulcers and Uloric (TMX 67) for gout, approved in
January and February 2009, will give TPNA two new drug launches in the
first half of 2009 in the US.
Blopress expansions Blopress was the best selling pharmaceutical product in Japan in the year
ending September 2008 according to IMS. Takeda is developing a
fixed-dose combination of candesartan with the calcium antagonist
amlodipine in Japan, which will combine two of Japan’s best selling
drugs. Takeda and AstraZeneca’s combination of candesartan cilexetil
and hydrochlorothiazide (Blopress Comp) is available in most markets
worldwide for the treatment of hypertension and approval as Ecard was
granted in Japan in January 2009.
© 2009 IMS Health In cor po rated or its af fil i ates Page 14